These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 705679)

  • 1. [Cardiovascular complications of oestrogen treatment in prostatic carcinoma (author's transl)].
    Héritier P; Hessler D
    Ther Umsch; 1978 Oct; 35(10):841-4. PubMed ID: 705679
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effects of oestrogens on cardiovascular risk factors in patients with carcinoma of the prostate (author's transl)].
    Varenhorst E; Carlström K; Karlberg BE; Risberg B; Wallentin L; Wranne B
    Urologe A; 1982 Jan; 21(1):34-8. PubMed ID: 6805122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular complications to treatment of prostate cancer with estramustine phosphate (Estracyt) or conventional estrogen. A follow-up of 212 randomized patients.
    Hedlund PO; Gustafson H; Sjögren S
    Scand J Urol Nephrol Suppl; 1980; 55():103-5. PubMed ID: 6938012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Orchidectomy and oestrogen therapy of carcinoma of the prostate (author's transl)].
    Straube W; Braun JS
    Urologe A; 1974 Jul; 13(4 Pt A):198-201. PubMed ID: 4137442
    [No Abstract]   [Full Text] [Related]  

  • 5. [Carcinoma of the breast under estrogen-treatment for prostatic carcinoma (author's transl)].
    Bülow H; Wullstein HK; Böttger G; Schröder FH
    Urologe A; 1973 Sep; 12(5):249-53. PubMed ID: 4357698
    [No Abstract]   [Full Text] [Related]  

  • 6. Oestrogens: are they really dangerous? Groupe Coopératif d'étude sur le Cancer de la Prostate.
    Prog Clin Biol Res; 1987; 243B():437-8. PubMed ID: 3659036
    [No Abstract]   [Full Text] [Related]  

  • 7. [Vascular accidents of estrogen therapy for prostatic cancer metastases].
    Jurascheck F
    J Urol Nephrol (Paris); 1973 Dec; 79(12 Pt 2):400-2. PubMed ID: 4804405
    [No Abstract]   [Full Text] [Related]  

  • 8. [Cardiovascular effects of estrogen in prostatic cancer].
    Hedlund PO
    Lakartidningen; 1981 May; 78(22):2215-7. PubMed ID: 7196479
    [No Abstract]   [Full Text] [Related]  

  • 9. [Cardiovascular risks induced by estrogens prescribed at low doses. 208 years of observation--137 patients].
    Chevret S; Chastang C
    Prog Urol; 1991 Apr; 1(2):281-5. PubMed ID: 1844829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Estrogens and postmenopause (author's transl)].
    Rezaković-Musić D
    Lijec Vjesn; 1981; 103(2-3):97-104. PubMed ID: 7031394
    [No Abstract]   [Full Text] [Related]  

  • 11. [Inhibition of platelet aggregation under estrogen-treatment in patients with carcinoma of the prostate (author's transl)].
    Eisen M; Napp HE; Vock R
    Urologe A; 1975 May; 14(3):132-6. PubMed ID: 1154559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Changes in hormonal homeostasis and development of disorders of the cardiovascular system in patients with prostatic cancer on estrogen therapy].
    Gembitskiĭ EV; Begunov AV
    Klin Med (Mosk); 1991 Dec; 69(12):59-63. PubMed ID: 1724022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen and survival data in carcinoma of the prostate.
    Bennett AH; Dowd JB; Harrison JH
    Surg Gynecol Obstet; 1970 Mar; 130(3):505-8. PubMed ID: 4905115
    [No Abstract]   [Full Text] [Related]  

  • 14. [Hyperplasia of prolactin cells after estrogen therapy in carcinoma of the prostate (author's transl)].
    Hachmeister U
    Verh Dtsch Ges Pathol; 1972; 56():535-9. PubMed ID: 4130889
    [No Abstract]   [Full Text] [Related]  

  • 15. [The curative treatment of prostatic carcinoma (author's transl)].
    Graber P
    Ther Umsch; 1978 Oct; 35(10):845-8. PubMed ID: 705680
    [No Abstract]   [Full Text] [Related]  

  • 16. [Parenteral estrogen--a safe therapeutic alternative in prostatic cancer seen from the cardiovascular point of view?].
    Henriksson P; Stege R; Collste L; Pousette A; Von Schoultz B; Carlström K
    Lakartidningen; 1992 Oct; 89(42):3493-4, 3497. PubMed ID: 1435052
    [No Abstract]   [Full Text] [Related]  

  • 17. [Intra- and extracellular electrolyte concentration of estrogen therapy on patients with carcinoma of the prostate (author's transl)].
    Kunze U; Orestano F
    Urologe A; 1973 Sep; 12(5):274-7. PubMed ID: 4762689
    [No Abstract]   [Full Text] [Related]  

  • 18. [Prostatic carcinoma: metabolic effect of percutaneous beta-estradiol (author's transl)].
    Steg A; Benoit G; Limouzin-Lamotte A; Mahoudeau J; Caillens M; Raichvarg D
    Nouv Presse Med; 1979 Nov; 8(46):3801-2. PubMed ID: 534245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polyestradiol phosphate (160 mg/month) or LHRH analog (buserelin depot) in the treatment of locally advanced or metastasized prostatic cancer. The Finnprostate Group.
    Aro J; Ruutu M; Juusela H; Hansson E; Permi J
    Ann Chir Gynaecol Suppl; 1993; 206():5-8. PubMed ID: 8291869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Experiences in the treatment of advanced prostatic cancer using Turisteron with special reference to cardiovascular complications].
    Drawz B; Hoffmann L; Drawz G; Russbüldt R
    Z Urol Nephrol; 1987 Mar; 80(3):171-5. PubMed ID: 3604473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.